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Abstract
A series of novel 7-(N-substituted-methyl)-camptothecin derivatives was designed, synthesized,
and evaluated for in vitro cytotoxicity against four human tumor cell lines, A-549, MDA-MB-231,
KB, and KBvin. All of the derivatives showed promising in vitro cytotoxic activity against the
tested tumor cell lines, with IC50 values ranging from 0.0023 to 1.11 μM, and were as or more
potent than topotecan. Compounds 9d, 9e, and 9r exhibited the highest antiproliferative activity
among all prepared derivatives. Furthermore, all of the compounds were more potent than
paclitaxel against the multidrug-resistant (MDR) KBvin subline. With a concise efficient synthesis
and potent cytotoxic profiles, especially significant activity towards KBvin, compounds 9d, 9e,
and 9r merit further development as a new generation of camptothecin-derived anticancer clinical
trial candidates.
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Camptothecin (CPT, 1, Figure 1), a natural quinoline alkaloid isolated by Wall and Wani
from the Chinese tree Camptotheca acuminata, showed potent antiproliferative activity
against a broad spectrum of tumors.1-3 Its antitumor activity is induced by directly binding
to topoisomerase I (Topo I), which results in interference with the catalytic cycle of DNA-
Topo I and stabilization of the DNA-Topo I binary complex.4-6 Based on CPT’s remarkable
anticancer activity and unique cytotoxic mechanism, numerous potent CPT analogs have
been developed. Among them, two Topo I inhibitors, topotecan (2) and irinotecan (3), have
been used successfully in the clinic as anticancer drugs, while several other analogs are the
subjects of ongoing preclinical or clinical evaluation.7-10
Although CPT derivatives remain a promising class of antitumor agents, the highly
electrophilic α-hydroxylactone of the E ring is intrinsically unstable and undergoes rapid
hydrolysis to the biologically inactive carboxylate form under physiological conditions.11,12
This chemical feature diminishes the efficacy of various CPT derivatives in vivo compared
to the impressive results often obtained from in vitro studies. Thus, several synthetic
strategies to overcome this challenge have been developed, resulting in a logical mapping of
the structure–activity relationship (SAR) of CPT derivatives.13,14 Substitutions at the 11- or
5-position are not well tolerated, whereas various substituents at the 7-, 9-, or 10-position
can improve the antitumor activity, as well as increase E-ring stability.11,15,16 In particular,
previous studies documented that the introduction of lipophilic substituents at the 7-position
provides favorable molecular interactions and improved pharmacological features that could
have potential therapeutic advantages.17 A binding model of CPT with biological
macromolecules also indicated that the C-7 molecular area could accommodate considerable
structural diversity.18-20 On the basis of these critical clues, various substitutions, such as
ethyl, alkylsilyl, oxyiminoalkyl, and alkylsilylalkyl, were introduced at the 7-position of
CPT to produce potent antitumor agents. To date, 7-substituted compounds constitute most
of the second-generation CPT analogs that have reached preclinical or clinical development
studies. Examples include gimatecan (4),21 CKD-602 (5),22 and BNP-1350 (6),23 which
contain highly lipophilic substituents intended to increase antitumor activity. These
successful examples indicate the important role played by various C-7 substitutions in the
activity profiles of CPT analogs and the feasibility of optimizing this compound class
through rational C-7 modification.
In our continuing studies on the chemistry of CPT,24-30 we recently reported a series of 7-
ketone camptothecin derivatives with potent antitumor activity and significantly different
drug-resistance profiles from those of the parent compound.30 Some of the new compounds
exhibited activity comparable to that of marketed CPTs, such as 2 and 3. Notably, some
compounds displayed promising cytotoxicity against KBvin cells, while 3 lost activity
completely. The encouraging preliminary results have prompted us to extend our
investigation by synthesizing a novel series of 7-(N-substituted-methyl)-camptothecin
derivatives. Herein, we describe our introduction of different nitrogen substituted groups
into the 7-position of CPT via a coupling reaction and cytotoxic activity studies on the
resulting compounds.
The synthetic route to target CPT derivatives 9a-s is depicted in Scheme 1. Briefly,
treatment of 1 with hydrogen peroxide and ferrous sulfate in an aqueous methanol-sulfuric
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acid solution furnished 7-hydroxymethylcamptothecin (7) in 80% yield.31 Precursor 7 was
converted into the key intermediate 7-bromomethylcamptothecin (8) in 66% yield by
heating in hydrobromic acid.32 Intermediate 8 was coupled with various substituted amines
in dry DMF to afford the desired derivatives 9a-s in 21–46% yields.33 All synthesized target
compounds were purified by column chromatography, and their structures were
characterized by 1H-NMR, MS, and elemental analysis.
Target compounds 9a-s were evaluated for in vitro cytotoxicity against a panel of human
tumor cell lines, including A-549 (lung carcinoma), MDA-MB-231 (triple-negative breast
cancer), KB (originally isolated from nasopharyngeal carcinoma), and KBvin (MDR KB
subline), using a sulforhodamine B colorimetric (SRB) assay with triplicate
experiments.34,35 Paclitaxel and 2 were used as positive controls and the screening results
are shown in Table 1.
As illustrated in Table 1, all new compounds exhibited significant in vitro cytotoxic activity
against the four tested tumor cell lines, with IC50 values ranging from 0.0023 to 1.11 μM,
and except for 9k, 9q, and 9s, were mostly more active than 2, a clinically used CPT-derived
chemotherapeutic drug. Compounds 9d, 9e, and 9r were the most potent compounds in the
series and were also superior to paclitaxel against the A-549 cell line, which was generally
most sensitive to these CPT derivatives. Against the same cell line, many compounds,
including 9d–9f, 9h, 9j, 9m–9o, and 9r, also showed better antiproliferative activity than 2.
With few exceptions (i.e., 9k, 9q, and 9s), the tested compounds showed increased cytotoxic
potency against the triple-negative breast cancer (MDA-MB-231) cell line compared with 2.
With regard to the KB cell line, seven compounds exhibited significant cytotoxic activity
comparable to that of 2. Remarkably, except for 9q, all of the compounds (IC50 0.0128–
0.274 μM) were more potent than paclitaxel (IC50: 1.44 μM) and 2 (IC50 0.396 μM) against
the KBvin subline. These encouraging results suggested that these new derivatives could
overcome the MDR phenotype overexpressing P-glycoprotein. Notably, the three most
promising compounds 9d, 9e, and 9r showed broad in vitro antitumor spectra and were
about 7- to 20-fold more potent than 2. Further pharmacological, toxicological evaluations
and binding affinity analysis with DNA-Topo I target in the modeling of these promising
compounds are in progress.
SAR analysis of the results from the synthesized compounds revealed several structural
properties that could influence the in vitro cytotoxicity of the new CPT derivatives.
Regarding compounds 9a to 9j with substituted (phenylamino)methyl groups at C-7,
derivatives with m-/p-chlorophenyl rings (9f and 9i) exhibited lower activity than their o-
substituted isomer 9j. Similarly, the relocation of an electron-donating methoxy group from
the o-position (9d, IC50 0.0023μM) to the p-position (9c, IC50 0.0470 μM) also decreased
the cytotoxicity remarkably. These results suggested that an o-substituted phenyl group is
more favorable than m-/p-substitued rings for better activity. Moreover 9e and 9f with p-
fluoro and p-chloro substitution, respectively, on the phenyl ring were more potent against
A-549 tumor cells than 9g with p-bromo substitution, indicating that a substituent’s size, in
addition to position, could affect the activity. However, the presence of a pyridine-2-yl
rather than phenyl group on the amine did not substantially change the cytotoxic activity (9l
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vs 9a). Among compounds 9m–9s with non-aromatic amino substituents, the SAR analysis
showed that the alkyl variant had an important effect on the in vitro cytotoxic activity. For
example, the cytotoxic activity of 9r with a (propylamino)methyl group at C-7 was
significantly greater than that of compounds with a (cyclohexylamino)methyl (9m) or
(diisopropylamino)methyl (9q) moiety. These data suggested that the bulkier substituents in
the two latter compounds might produce steric hindrance at the target level and thus lower
the cytotoxic activity. The polarity and electron density in the C-7 side chain were also
important, as changing the propylamino group in 9r to a 2-hydroxyethylamino group in 9s
greatly decreased the cytotoxic activity (e.g., IC50 0.0048 μM for 9r vs 0.15 μM for 9s
against A-549). Taken together, these results showed that both the identity and substitution
pattern in the R group at C-7 could greatly influence the cytotoxicity of the new CPT
derivatives
In summary, 19 novel 7-(N-substituted)-methyl-camptothecin derivatives were designed,
synthesized, and evaluated for antiproliferative activity against four human tumor cell lines
(A-549, MDA-MB-231, KB and KBvin) by using a sulforhodamine B colorimetric assay.
Most of the new derivatives showed comparable or superior antiproliferative activity
compared with 2. In particular, compounds 9d, 9e, and 9r were the most promising
derivatives with 7- to 20-fold greater potency than 2 against the A-549 cell line and were
selected as lead molecules for further development. Notably, with IC50 values ranging from
0.0128 to 1.06 μM, all of the compounds also were more potent than paclitaxel (IC50 1.44
μM) against KBvin cells. Furthermore, SAR study indicated that both N-aromatic and N-
aliphatic substituents at C-7 can produce potent activity, while selected variation of these
substituents can greatly affect the activity. These findings support our further optimization
of CPT to develop potential anticancer drug candidates. Continuing studies to substantiate
and improve activity profiles are underway in our laboratories and will be reported in due
course.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work was supported financially by the National Natural Science Foundation of China (30800720, 31371975),
the Fundamental Research Funds for the Central Universities (lzujbky-2013-69), and the Foundation of Priority
Forestry Disciplines in Zhejiang A&F University (KF201325). Partial support was also supplied by NIH grant
CA177584 from the National Cancer Institute awarded to K.H. Lee. Thanks are also due to the support of Taiwan
Department of Health Cancer Research Center of Excellence (DOH-100-TD-C-111-005).
References
1. Oberlies NH, Kroll DJ. J. Nat. Prod. 2004; 67:129. [PubMed: 14987046]
2. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH. J. Nat. Cancer Inst. 1993; 85:271.
[PubMed: 8381186]
3. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail A, Sim GA. J. Am. Chem. Soc. 1966;
88:3888.
4. Hsiang YH, Hertzberg R, Hecht S, Liu LF. J. Biol. Chem. 1985; 260:14873. [PubMed: 2997227]
5. Takimoto CH, Wright J, Arbuck SG. Biochim. Biophy. Acta. 1998; 1400:107.
Zhao et al. Page 4






















6. Pommier Y. Nat. Rev. Cancer. 2006; 6:789. [PubMed: 16990856]
7. Liew ST, Yang LX. Curr. Pharm. Des. 2008; 14:1078. [PubMed: 18473856]
8. Lorence A, Nessler CL. Phytochem. 2004; 65:2735.
9. Thomas CJ, Rahier NJ, Hecht SM. Bioorg. Med. Chem. 2004; 12:1585. [PubMed: 15028252]
10. Lerchen HG. Drugs of the Future. 2002; 27:869.
11. Adams DJ. Curr. Med. Chem. - Anti-Cancer Agents. 2005; 5:1.
12. Tobin PJ, Rivory L. Pl Drug Design Reviews - Online. 2004; 1:341.
13. Verma RP, Hansch C. Chem. Rev. 2009; 109:213. [PubMed: 19099450]
14. Sriram D, Yogeeswari P, Thirumurugan R, Bal TR. Nat. Prod. Res. 2005; 19:393. [PubMed:
15938148]
15. Bom D, Curran DP, Kruszewski S, Zimmer SG, Strode JT, Kohlhagen G, Du W, Chavan AJ,
Fraley KA, Bingcang AL, Latus LJ, Pommier Y, Burke TG. J. Med. Chem. 2000; 43:3970.
[PubMed: 11052802]
16. Leary JO, Muggia FM. Eur. J. Cancer. 1998; 34:1500. [PubMed: 9893620]
17. Pisano C, De Cesare M, Beretta GL, Zuco V, Pratesi G, Penco S, Vesci L, Foderà R, Ferrara FF,
Guglielmi MB, Carminati P, Dallavalle S, Morini G, Merlini L, Orlandi A, Zunino F. Mol. Cancer
Ther. 2008; 7:2051. [PubMed: 18645015]
18. Redinbo RR, Stewart L, Kuhn P, Champoux JJ, Hol WGJ. Science. 1998; 279:1504. [PubMed:
9488644]
19. Fan J, Weinstein JN, Kohn KW, Shi LM, Pommier Y. J. Med. Chem. 1998; 41:2216. [PubMed:
9632354]
20. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Stewart L. Proc. Natl. Acad. Sci.
U.S.A. 2002; 99:15387. [PubMed: 12426403]
21. Dallavalle S, Ferrari A, Biasotti B, Merlini L, Penco S, Gallo G, Marzi M, Tinti MO, Martinelli R,
Pisano C, Carminati P, Carenini N, Beretta G, Perego P, Cesare MD, Pratesi G, Zunino F. J. Med.
Chem. 2001; 44:3264. [PubMed: 11563925]
22. Ahn SK, Choi NS, Jeong BS, Kim KK, Journ DJ, Kim JK. J. Heterocycl Chem. 2000; 37:1141.
23. Boven E, Van Hattum AH, Hoogsteen I, Schluper HM, Pinedo HM. Ann. N.Y. Acad. Sci. 2000;
922:175. [PubMed: 11193892]
24. Wang HK, Liu SY, Hwang KM, Taylor G, Lee KH. Bioorg.Med.Chem. 1994; 2:1397–1402.
[PubMed: 7788302]
25. Wang HK, Lin SY, Hwang KM, McPhail AT, Lee KH. Bioorg.Med. Chem. Lett. 1995; 5:77.
26. Ohtsu H, Nakanishi Y, Bastow KF, Lee FY, Lee KH. Bioorg. Med. Chem. 2003; 11:1851.
[PubMed: 12659771]
27. Ye DY, Shi Q, Leung CH, Kim SW, Park SY, Gullen EA, Jiang ZL, Zhu H, Morris-Natschke SL,
Cheng YC, Lee KH. Bioorg. Med. Chem. 2012; 20:4489. [PubMed: 22698783]
28. Yang L, Zhao CY, Liu YQ. J. Braz. Chem. Soc. 2011; 22:308.
29. Liu YQ, Tian X, Yang L, Zhan ZC. Eur. J. Med. Chem. 2008; 43:26104.
30. Liu YQ, Dai W, Wang CY, Morris-Natschke SL, Zhou XW, Yang L, Yang XM, Li WQ, Lee KH.
Bioorg. Med. Chem. Lett. 2012; 22:7659. [PubMed: 23102893]
31. Sawada S, Nokata K, Furuta T, Yokokura T, Miyasaka T. Chem. Pharm. Bull. 1991; 39:2574.
[PubMed: 1806276]
32. Synthesis of key intermediate 7-bromomethylcamptothecin (8). To a solution of 7-
hydroxymethylcamptothecin (7) (300 mg, 0.80 mmol) in HBr (40%, 40 mL), 98% H2SO4 (0.1
mL) was added and the mixture was heated at reflux for 16 h. After completion of the reaction, the
solvent was evaporated under vacuum and the residue recrystallized from MeOH to provide 7-
bromomethylcamptothecin (8) as a light brown solid (234 mg, 66% yield). 1H NMR (400 MHz,
DMS0-d6) δ: 0.87 (t, J=7.2Hz, 3H, 19-H), 1.84-1.90 (m, 2H, 18-H), 5.26 (s, 2H, −CH2-), 5.28 (s,
2H, 5-H), 5.45 (s, 2H, 17-H), 6.50 (s, 1H, 20-OH), 7.33 (s, 1H, 14-H), 7.76 (t, J=7.2Hz, 1H, 11-
H), 7.89 (t, J=7.2Hz, 1H, 10-H), 8.21 (d, J=8.4Hz, 1H, 12-H), 8.42 (d, J=8.4Hz, 1H, 9-H); MS-
ESI m/z: 441.4 [M+H]+; Anal. Calc. For C21H17N2O4Br: C 57.16%, H 3.88%, N 6.35%. Found:
C 57.17%, H 3.88%, N 6.34%.
Zhao et al. Page 5






















33. General synthetic procedure for target compounds 9a-s. To a solution of 7-
bromomethylcamptothecin (0.1 mmol) in dry DMF (15mL), different amines (0.15 mmol)
dissolved in toluene (5 mL) were added and the reaction mixture was stirred at room temperature
for 12 h. After the reaction was completed, the mixture was evaporated to dryness and the residue
was purified by chromatography on silica gel using CHCl3/MeOH as eluant to give 9a-s.
Representative analytical and spectroscopic data of 7-(N-(2-methoxyphenylamino)methyl)-(20S)-
camptothecin (9d). Yield 39%; m.p. 239-241 °C; 1H NMR (400 MHz, DMSO-d6) δ: 0.85 (t,
J=7.2Hz, 3H, 19-H), 1.79-1.86 (m, 2H, 18-H), 3.85 (s, 3H, −OCH3), 5.01 (d, J=4.8Hz, 2H,
−CH2-), 5.21 (s, 2H, 5-H), 5.43 (s, 2H, 17-H), 5.90 (m, 1H, NH), 6.35 (d, J=7.6Hz, 1H, Ar-H),
6.52 (s, 1H, 20-OH), 6.53-6.57 (m ,1H, Ar-H), 6.61-6.65 (m, 1H, Ar-H), 6.87 (d, J=8.0Hz, 1H, Ar-
H), 7.30 (s, 1H, 14-H), 7.72 (t, J=7.2Hz, 1H, 11-H), 7.86 (t, J=7.2Hz, 1H, 10-H), 8.17 (d,
J=8.4Hz, 1H, 12-H), 8.49 (d, J=8.4Hz, 1H, 9-H); MS-ESI m/z: 484.9 [M+H]+; Anal. Calc. For
C28H25N3O5: C 69.55%, H 5.21%, N 8.69%. Found: C 69.56%, H 5.23%, N 8.67%.
34. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H,
Kenney S, Boyd MR. J. Natl. Cancer Inst. 1990; 82:1107. [PubMed: 2359136]
35. Cytotoxic activity was determined by the sulforhodamine B (SRB) colorimetric assay as previously
described.34 In brief, the cells (4,000–7,500 cells/well) were seeded with various concentrations of
samples in 96-well plates filled with RPMI-1640 medium containing 10 mM HEPES and 2 mM L-
glutamine (HyClone) supplemented with 10% fetal bovine serum (HyClone), 100 μg/mL
streptomycin, 100 IU/mL penicillin, and 0.25 μg/mL amphotericin B (Cellgro). After 72 h
incubation at 37 °C with 5% CO2 in air, the living cells were fixed in 10% trichloroacetic acid for
30 min followed by staining with 0.04% SRB (Sigma Chemical Co.) for 30 min. The bound SRB
was solubilized with 10 mM Tris-base and the absorbance was measured at 515 nm using a
Microplate Reader ELx800 (Bio-Tek Instruments, Winooski, VT) operated by a Gen5 software.
All results were representative of three or more experiments and IC50 is expressed as the average
with standard deviation (SD).
Zhao et al. Page 6























Structures of camptothecin (1), topotecan (2), irinotecan (3), gimatecan (4), CKD-602 (5),
and BNP-1350 (6).
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Synthesis of target compounds 9a-s.
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Table 1
Antiproliferative activity of 9a-s against four human tumor cell lines
Compd
IC50 (μM) with SD
A-549 MDA-MB-231 KB KBvin
9a 0.0532±0.0226 0.0781±0.0178 0.0783±0.0272 0.0479±0.0126
9b 0.0587±0.0262 0.0927±0.0187 0.0817±0.0201 0.0795±0.0411
9c 0.0470±0.0191 0.0842±0.0062 0.0758±0.0107 0.0773±0.0255
9d 0.0023±0.0024 0.0264±0.0125 0.0046±0.0032 0.0149±0.0121
9e 0.0063±0.0027 0.0300±0.0163 0.0050±0.0013 0.0132±0.0055
9f 0.0391±0.0173 0.0644±0.0306 0.0397±0.0015 0.0129±0.0066
9g 0.0592±0.0252 0.114±0.0464 0.0821±0.0093 0.0633±0.0177
9h 0.0362±0.0211 0.0640±0.0025 0.0615±0.0119 0.0780±0.0853
9i 0.0504±0.0206 0.0961±0.0102 0.0713±0.0139 0.0688±0.0315
9j 0.0170±0.0115 0.0576±0.0514 0.0371±0.0031 0.0128±0.0081
9k 0.122±0.0406 0.337±0.0114 0.180±0.0662 0.117±0.0177
91 0.0514±0.0211 0.108±0.0197 0.0786±0.0058 0.0706±0.0217
9m 0.0188±0.0154 0.0532±0.0006 0.0362±0.0153 0.0165±0.0149
9n 0.0219±0.0107 0.0699±0.0043 0.0499±0.0074 0.0205±0.0141
9o 0.0155±0.0059 0.0609±0.0096 0.0371±0.0018 0.0208±0.0199
9p 0.0622±0.0168 0.110±0.0177 0.0895±0.0231 0.274±0.1592
9q 0.534±0.0701 1.11±0.0059 0.813±0.0556 1.06±0.0115
9r 0.0048±0.0042 0.0316±0.0026 0.0150±0.0102 0.0217±0.0157
9s 0.150±0.0275 0.378±0.0082 0.208±0.0209 0.183±0.0219
2 0.0452±0.0004 0.102±0.0055 0.0625±0.0042 0.396±0.0207
Paclitaxel 0.0057±0.0016 0.0066±0.0018 0.0039±0.0010 1.44±0.137
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